ORPHA:244242
HELLP syndrome
Also known as: Hemolysis, elevated liver enzymes, low platelets in pregnancy · Hemolysis-elevated liver enzymes-low platelets syndrome
Publications
11,774
Trials
13
Interventional, condition-specific
Researchers
1,144
Distinct authors in sample
Gene link
—
Readiness
3/6
Stages with a signal
Clinical definition (Orphanet)
A rare hemorrhagic disorder due to an acquired platelet anomaly characterized by hemolysis, elevated liver enzymes and thrombocytopenia that affects pregnant or post-partum women, and is frequently associated with severe preeclampsia. Symptoms are variable, typically including right upper quadrant or epigastric abdominal pain, nausea, vomiting, excessive weight gain, generalized edema, hypertension, general malaise, right shoulder pain, backache, and/or headache. Hepatic hemorrhage and rupture, renal failure, and pulmonary edema can result in maternal and/or fetal death.
How rare: How common this is has not been clearly measured.
Cross-references
Joined from Mondo / Orphanet. MeSH labels may enter searches; UMLS / OMIM / NCIT are stored for reference.
- MONDO:0008585
- MeSH:D017359
- UMLS:C0162739
- NCIT:C84750
Additional Mondo synonyms (3)
hemolysis, elevated liver enzymes, low platelets in pregnancy · hemolysis-elevated liver enzymes-low platelet count syndrome · hemolysis-elevated liver enzymes-low platelets syndrome
Research stages
Trial readiness signals
Where this condition sits on an open-data research pipeline — not how close a treatment is, and not medical advice. Empty stages often mean “not in these databases under this Mondo ID,” not “impossible.”
3/6 stages with a signal
An interventional trial matched this condition name on ClinicalTrials.gov — see trials below.
- Gene identifiedNot found
No GenCC disease–gene assertion in this build
- LiteraturePresent
11,774 matched papers (7,309 in last 10 years) Source
- Phenotype characterisedPresent
29 HPO annotations (e.g. Proteinuria; Nausea; Back pain) Source
- Animal modelNot found
No Alliance genotype “model of” associations via Monarch for these Mondo IDs
- Orphan designationNot found
No FDA or EMA orphan-drug designation matched this disease via UMLS or preferred name Source
- Interventional trialPresent
13 matched on ClinicalTrials.gov (2 recruiting in sample)
Biology
Genes and phenotypes
Gene–disease validity from GenCC, plus phenotypes and animal models joined from Monarch Initiative via Mondo ID — not a clinical diagnosis aid.
Do we know what causes it?
Not yet — the cause hasn't been pinned down in GenCC.
No strong gene–disease assertion joined for this Orphanet entity.
Phenotypes (Monarch / HPO)
29
Associated phenotypes · MONDO:0008585
- Proteinuria
- Nausea
- Back pain
- Disseminated intravascular coagulation
- Placental abruption
Showing 5 of 29 — open Monarch for the full list.
Animal models (Monarch / Alliance)
None returned for this Mondo ID. Empty here is not proof that no model organism work exists under another name or gene.
Monarch fetch 2026-07-29
Therapies
Designations, candidates, and chemicals
FDA OOPD and EMA orphan designations, Open Targets clinical candidates, and CTD chemical associations via MyDisease.info. These never change the interventional-trial headline.
Orphan designation (FDA · EMA)
No designation matched this disease via UMLS or preferred name on the FDA OOPD mirror or EMA orphan register. Absence here is not proof that none exists under another wording.
Open Targets candidates
3
Drugs / clinical candidates · MONDO_0008585
- DEXAMETHASONE·phase 3
- RAVULIZUMAB·phase 2
- ECULIZUMAB·phase 1
CTD chemicals (MyDisease.info)
No CTD chemical associations returned for this Mondo ID.
Literature
Is anyone studying this?
11,774
11,774 papers — among the better-studied rare conditions, though still a fraction of common-disease literature (breast cancer: over 700,000). Median papers in the last 10 years for a rare disease in this dataset (publications denominator n=3967) is 59.
11,774 papers since the earliest indexed year in this search — median last-10-year count for a rare disease in this dataset is 59 (publications denominator n=3967).
7,309 in the last 10 years · low confidence
Phrase hits: 9,974 · MeSH hits: 319
Who's working on it?
1,144
Distinct author names in 200 sampled papers — named people below.
Who's working on it?
People publishing on this condition (sampled Europe PMC records). Affiliation is the most recent found in that sample.
- 01Karaaslan O4 papers · 2026
Department of Obstetrics and Gynaecology, Faculty of Medicine, Van Yüzüncü Yıl University, 65080 Van, Turkey.
Papers in Europe PMC - 02Karaman E4 papers · 2026
Department of Obstetrics and Gynaecology, Faculty of Medicine, Van Yüzüncü Yıl University, 65080 Van, Turkey.
Papers in Europe PMC - 03Li X4 papers · 2026
Department of Anaesthesiology, West China Second Hospital, Sichuan University, Chengdu, China.
Papers in Europe PMC - 04Onat E4 papers · 2026
Department of Obstetrics and Gynaecology, Faculty of Medicine, Van Yüzüncü Yıl University, 65080 Van, Turkey.
Papers in Europe PMC - 05Wilson ML4 papers · 2026
Department of Population and Public Health Sciences, Keck School of Medicine, University of Southern California, Los Angeles, CA 90033, USA.
Papers in Europe PMC - 06Ateş Ç3 papers · 2026
Department of Obstetrics and Gynaecology, Faculty of Medicine, Van Yüzüncü Yıl University, 65080 Van, Turkey.
Papers in Europe PMC - 07Doğan A3 papers · 2026
Department of Haematology, Faculty of Medicine, Van Yüzüncü Yıl University, 65080 Van, Turkey.
Papers in Europe PMC - 08Gjessing HK3 papers · 2026
Centre for Fertility and Health, Norwegian Institute of Public Health, 0379 Oslo, Norway.
Papers in Europe PMC - 09Hacıoğlu L3 papers · 2026
Department of Obstetrics and Gynaecology, Faculty of Medicine, Van Yüzüncü Yıl University, 65080 Van, Turkey.
Papers in Europe PMC - 10Joseph KS3 papers · 2026
Department of Obstetrics and Gynaecology, University of British Columbia, Vancouver, British Columbia, Canada.
Papers in Europe PMC
Clinical research
Is a treatment being tested?
13
interventional trials for this specific condition
13 interventional trials matched this specific condition name; 2 currently recruiting in our sample.
Data as of 11 September 2026
13 interventional trials — more than 77.2% of diseases in the trials denominator have none at all (5501 of 7126; this disease is at the 93.5th percentile).
low confidence · 93.5th percentile (trials denominator)
Recruiting interventional trials
From the matched ClinicalTrials.gov set
13 interventional trials matched after quoted-phrase search and title/condition post-filter.
- NCT07510568·NOT YET RECRUITING·Vitamin D Supplementation Among Pregnant Women in Uganda for the Prevention of Hypertensive Disorders in Pregnancy, and Other Adverse Maternal and Foetal Outcomes
Not reviewed·Conditions: Preeclampsia · Eclampsia · HELLP Syndrome·Matched via name + MeSH
- NCT06452498·NOT YET RECRUITING·Preeclampsia Intervention Netherlands
Not reviewed·Conditions: Pre-Eclampsia Onset Less Than 37 Weeks · Pre-Eclampsia · Pre-Eclampsia; Complicating Pregnancy · Pre-Eclampsia as Antepartum Condition·Matched via name + MeSH
Observational and natural-history studies
18 observational studies match this condition. These do not test a treatment and are not counted in the interventional-trial headline, but they are genuine research: natural-history work often defines the endpoints needed for a future rare-disease trial, and families may be able to enroll.
Recruiting or not-yet-recruiting
- NCT07209748·NOT YET RECRUITING·sCD163 in HELLP Syndrome
Not reviewed·Conditions: HELLP Syndrome Complicating Pregnancy·Matched via name + MeSH
- NCT07151339·RECRUITING·Pilot Project Renal and Cardiovascular Tertiary Prevention in Preeclampsia
Not reviewed·Conditions: Preeclampsia · HELLP Syndrome · Eclampsia · Kidney Disease·Matched via name + MeSH
- NCT06377878·RECRUITING·The Preeclampsia Registry
Not reviewed·Conditions: Preeclampsia · Eclampsia · HELLP Syndrome · Toxemia·Matched via name + MeSH
- NCT07377786·NOT YET RECRUITING·Study of Prognostic Values of Platelet Indices and Inflammatory Markers in Patients With HELLP Syndrome.
Not reviewed·Conditions: HELLP Syndrome·Matched via name + MeSH
- NCT05500989·RECRUITING·PlacEntal Acute Atherosis RefLecting Subclinical Atherosclerosis
Not reviewed·Conditions: Pre-Eclampsia · HELLP Syndrome · Intrauterine Growth Restriction · Pregnancy·Matched via name + MeSH
Other registries (secondary)
Broader net from EU CTIS, ISRCTN, and ICTRP when available — deduped against ClinicalTrials.gov IDs already counted above. Dual-model LLM relevance gates what we keep. These rows are not added to the interventional headline.
raw 49 · after dedupe 48 · already on CT.gov 0 · kept 0 · parent 0 · uncertain 48 · dropped 0 · fetched 2026-07-30
Source notes: ictrp: Error: ICTRP public search unavailable (WHO portal is SPA-only; SOAP needs partnership). Tried: https://apps.who.int/tri
No secondary-registry studies passed dual-model relevance for this condition name (after dedupe).
Uncertain / not reviewed (48)
- isrctn·ISRCTN31137599·No longer recruiting·PRETECH: a new point-of-care blood test to detect preeclampsia early and improve pregnancy care
skipped — LLM skipped (--skip-llm)
- isrctn·ISRCTN36032472·No longer recruiting·Evaluation of the safety of ovarian support cell in vitro maturation (OSC-IVM) application during in vitro fertilization procedures for infertility treatment
skipped — LLM skipped (--skip-llm)
- isrctn·ISRCTN86684235·Recruiting·Use of aspirin for the prevention of preeclampsia in twin pregnancies
skipped — LLM skipped (--skip-llm)
- isrctn·ISRCTN13720473·Recruiting·Simplified treatment for eclampsia prevention using magnesium sulfate
skipped — LLM skipped (--skip-llm)
- isrctn·ISRCTN12033893·No longer recruiting·Calcium supplementation for prevention of pre-eclampsia
skipped — LLM skipped (--skip-llm)
- isrctn·ISRCTN21187408·No longer recruiting·A study assessing clinical aspects of pregnancy, delivery and perinatal outcomes in women with intrahepatic cholestasis of pregnancy
skipped — LLM skipped (--skip-llm)
- isrctn·ISRCTN82984919·No longer recruiting·A feasibility study investigating pravastatin for the prevention of preterm birth in women
skipped — LLM skipped (--skip-llm)
- isrctn·ISRCTN16018898·No longer recruiting·OPTIMUM: Optimising titration and monitoring of maternal blood pressure
skipped — LLM skipped (--skip-llm)
- isrctn·ISRCTN17787139·Stopped·Randomised trial of pravastatin versus placebo for the prevention of high blood pressure in pregnancy
skipped — LLM skipped (--skip-llm)
- isrctn·ISRCTN40384046·No longer recruiting·Prediction of Risks in Early onset Pre-eclampsia (PREP)
skipped — LLM skipped (--skip-llm)
- isrctn·ISRCTN05689407·No longer recruiting·Preterm Premature Rupture Of Membranes between 34 and 37 weeks: EXpectant management versus Induction of Labour 2
skipped — LLM skipped (--skip-llm)
- isrctn·ISRCTN26532492·No longer recruiting·Outcome of modified Misgav Ladach (MML) method in first and second time caesarean deliveries
skipped — LLM skipped (--skip-llm)
- isrctn·ISRCTN45790835·No longer recruiting·Use of a nitric oxide (ISMN) for the PREVENTION and MANAGEMENT of pre-eclampsia (pilot study)
skipped — LLM skipped (--skip-llm)
- isrctn·ISRCTN52843371·No longer recruiting·Prevention of multiple pregnancies in couples with unexplained or mild male subfertility
skipped — LLM skipped (--skip-llm)
- isrctn·ISRCTN86744378·No longer recruiting·Treatment of couples with unexplained subfertility and an unfavourable prognosis: a randomised trial comparing the effectiveness of intrauterine insemination with ovarian hyperstimulation and in-vitro fertilisation with single embryo transfer
skipped — LLM skipped (--skip-llm)
- isrctn·ISRCTN08132825·No longer recruiting·Hypitat: Pregnancy-induced hypertension and pre-eclampsia after 36 weeks: induction of labour versus expectant monitoring. A comparison of maternal and neonatal outcome, maternal quality of life and costs.
skipped — LLM skipped (--skip-llm)
- isrctn·ISRCTN58496168·No longer recruiting·Aspirin and/or low-molecular weight heparin for women with unexplained recurrent miscarriages and/or intra-uterine foetal death
skipped — LLM skipped (--skip-llm)
- isrctn·ISRCTN86677348·No longer recruiting·Vitamins in Preeclampsia (VIP): a multicentre randomised clinical trial of vitamin C and E supplementation in pregnancy for the prevention of pre-eclampsia (India, Peru, Vietnam)
skipped — LLM skipped (--skip-llm)
- isrctn·ISRCTN62368611·No longer recruiting·A randomised controlled trial of vitamin C and E supplementation to prevent pre-eclampsia in women at risk
skipped — LLM skipped (--skip-llm)
- ctis·2024-519386-21-01·Expired·Pregnancy Outcomes: Effects of Metformin Study (POEM Study) a long term randomized controlled parallel group study in gestational diabetes mellitus
skipped — LLM skipped (--skip-llm)
- ctis·2023-510382-10-00·Authorised, ongoing·Metformin for the prolongation of pregnancy in preterm preeclampsia: the PI-NL trial
skipped — LLM skipped (--skip-llm)
- ctis·2023-503698-40-00·Authorised, ongoing·Aspirin versus placebo in twin pregnancies for preeclampsia prevention: A multicentre, randomised, double-blind, placebo-controlled trial (ASPRE-T)
skipped — LLM skipped (--skip-llm)
- ctis·2025-521257-17-00·Authorised, ongoing·DREPAMIR - A Phase 1/2 Open Label Cohort Comparative Study Evaluating the Efficacy and the safety of Gene Therapy of the Sickle Cell Disease by Transplantation of an Autologous CD34+ enriched cell fraction that contains autologous CD34+ cells transduced ex vivo by the bifunctional βAS3m/miR7m lentiviral vector expressing the βAS3m and a micro-RNA (miRNA) targeting specifically the endogenous βS-globin mRNA in Patients with Sickle Cell Disease (SCD)
skipped — LLM skipped (--skip-llm)
- ctis·2024-519709-37-00·Authorised·A Single Arm Study to Evaluate the Efficacy and Safety of Pozelimab and Cemdisiran Combination Therapy in Patients with Paroxysmal Nocturnal Hemoglobinuria with Inadequate Control of Intravascular Hemolysis on Currently Available C5 Inhibitor Therapy
skipped — LLM skipped (--skip-llm)
- ctis·2024-519746-70-01·Expired·A Phase 2, Double-blind, Randomized, Placebo-Controlled, Multicenter, Dose-Finding, Efficacy, and Safety Study of Tebapivat in Participants With Sickle Cell Disease
skipped — LLM skipped (--skip-llm)
Where to find support
Condition-specific patient organisations, when Orphanet lists them, are on the disease’s Orphanet page. We also link umbrella groups that support undiagnosed and ultra-rare families.
Orphanet entry for HELLP syndrome — check Associations / patient organisations on that page.
India — NPRD
Last verified 2026-07-26This ORPHAcode is not on our curated NPRD list (direct or Mondo-parent match). That does not decide clinical eligibility; families in India should ask a notified Centre of Excellence about current coverage.
Hand-curated for this project. ORPHAcode mappings are best-effort and may be incomplete or imprecise for umbrella categories. Parent (Mondo) matches mean the policy lists a broader category — confirm eligibility with a Centre of Excellence. Financial entitlements summarised from public policy statements and may change. This is not official government guidance.
How we counted this
Europe PMC query (preferred label + any corrected label + Orphanet and Mondo exact synonyms, stoplisted; unioned with resolved MeSH labels when available). UMLS / OMIM / NCIT cross-references are stored on the overview but are not added to the query string.
("HELLP syndrome" OR "Hemolysis, elevated liver enzymes, low platelets in pregnancy" OR "Hemolysis-elevated liver enzymes-low platelets syndrome" OR "hemolysis-elevated liver enzymes-low platelet count syndrome") OR (MESH:"HELLP Syndrome") OR ("HELLP" OR "HELLP-related")MeSH descriptor terms unioned into the query: HELLP Syndrome
ClinicalTrials.gov query (quoted phrases + MeSH via query.cond, plus recall-expansion terms when used):
"HELLP syndrome" OR "Hemolysis, elevated liver enzymes, low platelets in pregnancy" OR "Hemolysis-elevated liver enzymes-low platelets syndrome" OR "hemolysis-elevated liver enzymes-low platelet count syndrome"
Interventional trials matched via: both (mesh = registered under a MeSH descriptor no name phrase would catch; recall-expansion = gene / selected parent terms used only for trials).
Study-type breakdown: 13 interventional · 18 observational · 0 expanded access. Only interventional studies enter the trial headline.
Query health: ok — strategies attempted: phrase, mesh; with hits: phrase, mesh
Run this search on ClinicalTrials.gov
Confidence reasoning
- Preferred label is short or not clearly distinctive
- No synonyms dropped by stoplist
- No label/synonym collisions with other diseases in this corpus
- Publication count (11774) is extremely high with unknown/missing prevalence — treat as possible over-matching, not proven research intensity
Ingested 2026-07-27T10:28:54.380Z
